Considering that Th17-high patients are less sensitive or even unresponsive to ICS [59,66] and that asthma progression differs from more treatable Th2 types of the disease [67], developing an effective therapy targeting Th17/IL-17A axis would overcome a major unmet need in severe asthma. This evidence concerns the gene IL17A and asthma.